{"links":{"html":"https://www.erudio.com/reports/impassion050-nct03726879","json":"https://www.erudio.com/reports/impassion050-nct03726879.json","markdown":"https://www.erudio.com/reports/impassion050-nct03726879.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"impassion050-03726879"}},"request":"https://www.erudio.com/contact?report=impassion050-03726879"},"offer":{"cited_commentary_sources":16,"verified_hcp_statements":175,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":12,"optional":true,"price_per_verified_person_usd":15,"price_usd":180,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"impassion050-nct03726879"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=impassion050-03726879","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/impassion050-nct03726879","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_rule":"Standard: 151–300 verified statements","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T12:14:05.985650Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":15,"no_commentary_found":0},"aspects":[{"claim_count":5,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":4,"title":"Primary endpoint: Percentage of Participants With Pathological Complete Response (pCR) in the PD-L1-Positive Population (IC 1/2/3)"},{"claim_count":10,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":8,"title":"Primary endpoint: pCR in the ITT Population"},{"claim_count":11,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":6,"title":"Secondary endpoints"},{"claim_count":11,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":7,"title":"Population and setting"},{"claim_count":21,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":4,"title":"The comparison"},{"claim_count":13,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":4,"title":"Safety and tolerability"},{"claim_count":17,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":6,"title":"Design and conduct"},{"claim_count":25,"coverage":"discussed","id":"A1","source_count":10,"title":"Predictive biomarkers versus prognosis and response association"},{"claim_count":34,"coverage":"discussed","id":"A2","source_count":5,"title":"Alternative immune partners, earlier treatment and redesigned backbones"},{"claim_count":13,"coverage":"discussed","id":"A3","source_count":4,"title":"Chemotherapy omission and selection for de-escalation"},{"claim_count":13,"coverage":"discussed","id":"A4","source_count":3,"title":"Taxane preference, platinum shortages and pertuzumab access"},{"claim_count":12,"coverage":"discussed","id":"A5","source_count":3,"title":"HER2 loss, testing variability and subsequent HER2-directed treatment"},{"claim_count":11,"coverage":"discussed","id":"A6","source_count":5,"title":"Residual-disease T-DM1, postoperative escalation and benefit–tolerability trade-offs"},{"claim_count":5,"coverage":"discussed","id":"A7","source_count":1,"title":"Extended endocrine therapy: withholding after pCR and a high-risk exception"},{"claim_count":4,"coverage":"discussed","id":"A8","source_count":4,"title":"Initial reactions and the distinction between individual and organizational communication"}],"counts":{"cited_sources":22,"claims_by_expression_type":{"comparison":8,"experience":6,"interpretation":47,"opinion":32,"primary_context":27,"question":16,"restatement":16,"uncertainty":10,"unspecified":13},"claims_by_kind":{"interpretation":2,"limitation":1,"objective_result":4,"protocol_statement":15,"publication_statement":22,"source_observation":131},"clinician_statements":54,"evidence_units":102,"findings":10,"organisational_accounts":1,"people_cited":14,"people_identity_verified":12,"people_total":14,"screened_sources":41,"verified_claims":175},"findings_index":[{"id":"F1","structure":{"claims":24,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":9,"views":13},"has_counterview":true,"limitations":3,"links":{"context":3,"support":27},"ma_question":true,"named_voices":10,"passages":24,"sources":13,"sources_by_kind":{"commentary":9,"media":3,"publication":1}},"title":"Negative clinical-readiness judgments do not all have the same scope"},{"id":"F2","structure":{"claims":15,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":4,"views":9},"has_counterview":true,"limitations":3,"links":{"context":6,"support":17},"ma_question":true,"named_voices":3,"passages":8,"sources":5,"sources_by_kind":{"commentary":2,"media":1,"publication":2}},"title":"Toxicity is a central objection, but its mechanism remains a question"},{"id":"F3","structure":{"claims":14,"claims_by_group":{"comparisons":0,"experience":0,"questions":4,"restated":5,"views":5},"has_counterview":true,"limitations":3,"links":{"context":3,"support":17},"ma_question":true,"named_voices":4,"passages":15,"sources":6,"sources_by_kind":{"commentary":3,"media":1,"publication":2}},"title":"Endpoint choice and interrupted exposure constrain the long-term lesson"},{"id":"F4","structure":{"claims":25,"claims_by_group":{"comparisons":1,"experience":0,"questions":7,"restated":1,"views":16},"has_counterview":true,"limitations":3,"links":{"context":4,"support":26},"ma_question":true,"named_voices":8,"passages":17,"sources":10,"sources_by_kind":{"commentary":6,"media":3,"publication":1}},"title":"PD-L1 is questioned as a stand-alone selector, not replaced by a validated alternative"},{"id":"F5","structure":{"claims":35,"claims_by_group":{"comparisons":0,"experience":0,"questions":5,"restated":5,"views":25},"has_counterview":true,"limitations":4,"links":{"context":5,"support":36},"ma_question":true,"named_voices":3,"passages":16,"sources":4,"sources_by_kind":{"media":4}},"title":"A proposed response is to redesign combinations rather than abandon immunotherapy"},{"id":"F6","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":2,"questions":3,"restated":2,"views":6},"has_counterview":true,"limitations":5,"links":{"context":0,"support":14},"ma_question":true,"named_voices":3,"passages":10,"sources":4,"sources_by_kind":{"media":4}},"title":"Selective chemotherapy omission: a speaker reported non-use in the 2023 interview"},{"id":"F7","structure":{"claims":13,"claims_by_group":{"comparisons":3,"experience":4,"questions":2,"restated":1,"views":3},"has_counterview":false,"limitations":5,"links":{"context":0,"support":16},"ma_question":true,"named_voices":2,"passages":8,"sources":3,"sources_by_kind":{"media":3}},"title":"Backbone choices are shaped by tolerability and local access"},{"id":"F8","structure":{"claims":12,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":8,"views":0},"has_counterview":false,"limitations":3,"links":{"context":2,"support":12},"ma_question":true,"named_voices":2,"passages":9,"sources":3,"sources_by_kind":{"media":3}},"title":"Post-treatment HER2 loss is not treated as automatically removing HER2-directed benefit"},{"id":"F9","structure":{"claims":12,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":4,"views":5},"has_counterview":false,"limitations":5,"links":{"context":1,"support":14},"ma_question":true,"named_voices":2,"passages":9,"sources":5,"sources_by_kind":{"commentary":1,"media":2,"publication":2}},"title":"Residual disease supports T-DM1 while escalation raises benefit–tolerability questions"},{"id":"F10","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":4},"has_counterview":false,"limitations":2,"links":{"context":0,"support":5},"ma_question":true,"named_voices":1,"passages":3,"sources":1,"sources_by_kind":{"media":1}},"title":"Extended endocrine therapy is selectively considered, and explicitly withheld after pCR"}],"medical_affairs_question":"Which patients, partners and long-term endpoints could justify immunotherapy without reproducing toxicity on an already effective HER2-directed backbone?","sections":{"analysis":[{"id":"section-1","level":2,"title":"1. Negative judgments range from regimen-specific caution to categorical rejection"},{"id":"section-2","level":2,"title":"2. Safety concerns target both overlapping toxicity and treatment disruption"},{"id":"section-3","level":2,"title":"3. The pCR question and the exposure question are different limitations"},{"id":"section-4","level":2,"title":"4. Biological selection is the leading unresolved question, not a solved algorithm"},{"id":"section-5","level":2,"title":"5. Redesign proposals preserve optimism while changing the treatment architecture"},{"id":"section-6","level":2,"title":"6. De-escalation interest coexists with reasons to retain chemotherapy"},{"id":"section-7","level":2,"title":"7. Tolerability and access determine which backbone is realistic"},{"id":"section-8","level":2,"title":"8. HER2 reassessment raises a treatment-benefit question, not an automatic stopping rule"},{"id":"section-9","level":2,"title":"9. Post-neoadjuvant escalation starts from T-DM1, not from an empty comparator"},{"id":"section-10","level":2,"title":"10. Response can justify withholding further treatment, with a selective high-risk exception"},{"id":"section-11","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":2}],"id":"T1","label":"Primary endpoint: Percentage of Participants With Pathological Complete Response (pCR) in the PD-L1-Positive Population (IC 1/2/3)"},{"findings":[{"id":"F1","shared_claims":9},{"id":"F2","shared_claims":1}],"id":"T2","label":"Primary endpoint: pCR in the ITT Population"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":3}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":5},{"id":"F5","shared_claims":3},{"id":"F6","shared_claims":3}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F5","shared_claims":14},{"id":"F7","shared_claims":6}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":12},{"id":"F5","shared_claims":3}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":4},{"id":"F5","shared_claims":13}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T12:14:05.985650Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T12:28:02Z","record_hash":"d327137971f911723a1691b1a06e4099449bdc1c3ef7e4d23f0ba310c14087f9","release_hash":"7f119b00d5bed09c61d224220fc8d37711158357a87c67fd702866b78f5aaeaa","report_id":"erudio-nct03726879","run_id":"72a42fa8-f01e-45cb-a040-4674d06be7b1","schema_version":"5.0","slug":"impassion050-03726879","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"IMpassion050 asks whether adding atezolizumab to preoperative chemotherapy and dual HER2 blockade improves outcomes for patients with high-risk, early HER2-positive breast cancer. Commentary comes from X and LinkedIn posts, podcasts and YouTube discussions, including medical oncologists with confirmed clinical roles. The discussion turns on how broadly negative atezolizumab judgments apply, whether PD-L1 can guide immunotherapy selection, and whether redesigned immunotherapy combinations merit further study despite toxicity concerns.","meta_description":"41 sources screened · 175 verified statements (54 from clinicians verified by NPI or staff page) from 22 sources · 10 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-c44b618d0bf52de3de76"],"id":"F3","paraphrase":"An X post relays a question about whether pathological complete response is an appropriate endpoint for preoperative immunotherapy in IMpassion050.","publication_caveats":["The post passes along another person's question; it does not establish the poster's own view."],"source_channel":"x_thread","source_date":"2021-06-17","title":"Endpoint choice and interrupted exposure constrain the long-term lesson"},{"cited_claim_ids":["claim-545e8ec8c75cb6476e7f","claim-41d520c0057b7e65ddc9"],"id":"F9","paraphrase":"A podcast discussion asks about postoperative T-DM1 when preoperative treatment leaves residual disease. It also asks whether adding atezolizumab to T-DM1 in Astephania could improve outcomes.","publication_caveats":["These questions cannot be attributed to a named speaker in the sources reviewed for this edition.","The atezolizumab question concerns Astephania, a separate postoperative study, rather than an IMpassion050 result."],"source_channel":"podcast","source_date":"2024-02-16","title":"Residual disease supports T-DM1 while escalation raises benefit–tolerability questions"}]},"publication":{"approved_at":"2026-10-31T12:28:02Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":41},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","1 cited commentary passage leaves a source question open, such as who was speaking. The report attributes no further than the source shows.","Not yet captured in this edition: a question about substituting paclitaxel for an unclearly identified chemotherapy regimen.","Not yet captured in this edition: a question about paclitaxel substitution and its greater consideration when selecting the neoadjuvant chemotherapy backbone.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","83 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition are not a representative sample of HCP opinion; no prevalence, consensus percentage or independent-HCP count can be inferred.","Trial-name-centered searches can miss discussion that does not name IMpassion050, and some relevant passages were not fully assessed. Absence of a view in this report is not evidence that it was never expressed.","Some chemotherapy-free-strategy questions, response-definition qualifications and immediate-adoption context are not available as assessed statements, so the report cannot fully reconstruct that exchange.","Audio and video versions of the a speaker–another speaker interview describe the same conversation. Reposts relay material but do not independently establish endorsement.","Some recorded comments cannot be assigned to a named speaker and remain attributed only to the episode or discussion.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The final long-term analyses were descriptive, with small event counts and sample size determined for pCR. Numerical overall or subgroup differences are not established survival benefits.","Early discontinuation limits interpretation of the planned perioperative strategy, but the primary publication states that the coprimary pCR assessment was unaffected.","Fatal adverse events must not all be labeled treatment-related. Phase-specific safety reassurance must not be generalized to the whole study.","Descriptions of other studies, including regimen names and treatment-duration interpretations, are preserved as attributed commentary rather than silently corrected or treated as IMpassion050 findings.","Reported Canadian access constraints and institutional shortage adaptations describe their source settings and times, not universal or current reimbursement and practice.","The report does not establish current approval or labeling status."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":2,"other":0,"podcast":2,"publication":2,"registry":4,"regulatory":0,"x_thread":10,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":16,"methods":3,"results":3},"count":22,"evidence_window":{"end":"2026-10-23","start":"2021-06-17"},"retrieval_snapshot":"2026-10-31T10:45:44.771295Z","timeline":[{"count":2,"week":"2021-W24"},{"count":3,"week":"2022-W26"},{"count":1,"week":"2022-W28"},{"count":2,"week":"2023-W32"},{"count":1,"week":"2024-W07"},{"count":1,"week":"2024-W13"},{"count":1,"week":"2026-W14"},{"count":3,"week":"2026-W39"},{"count":1,"week":"2026-W40"},{"count":1,"week":"2026-W43"}],"undated_sources":6},"quote_policies":[{"id":"clinicaltrials:NCT03726879:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03726879:results","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03726879:context","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03726879:protocol:1","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03726879:sap:2","quote_policy":"short_quote_link_out"},{"id":"pubmed:35763704","quote_policy":"no_derivatives"},{"id":"pubmed:42785163","quote_policy":"no_derivatives"},{"id":"openfda:55889588-c5f1-d9bc-e063-6294a90a5791:20260709","quote_policy":"short_quote_link_out"},{"id":"openfda:c961a1ac-6705-4756-9abc-9d84a6fcb5c8:20260903","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7509891066305875968","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7510235683010211842","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:acda81","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:eac143","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1058020738177716224:8b41b4cd-ff10-41f0-ae56-ebcf671ccc52","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1340071713367863298:4dfb96e8-944a-4953-b5ca-be5f047a7855","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1405541331548532746:2323e205-bd12-4636-8269-500426c7bd1a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1405584013323026444:fe022931-ca8b-4e5a-9ad0-0c7167d0bcc0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1405587902365638659:ad392a9c-ca0b-4308-937e-57b6b98551ce","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1405591345562099722:dcf0a273-6032-4d7e-b121-04983820b589","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1405853201266585600:2ddc5018-5624-45e0-80d8-8839fb3e244a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1407397975484080131:80c29995-f9ed-476c-8904-8f3138ae4d48","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1407398328510390284:fc49baf8-90dc-4598-8ebc-c307ea30cacb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1541927107802157056:ac1cb84b-d886-4da5-9e60-f992f53c964d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1542099841643433990:345a24e5-06b8-4e3f-bbcb-758e11e9815d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1542100045125804035:c183284d-c9e9-4529-ad44-e712a93f05b0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1542150780194635781:7db06817-0c47-482c-8a78-b27a835d86a0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1542168583475716096:642117c3-768e-4755-beb8-f187b982d9a2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1542280104373813248:7ec8c135-c4bc-455f-812f-041e11612f5c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1545458189780541442:91001cec-ef33-416e-a1ef-79607066c839","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1547600568192884741:96bf9ae6-3da2-4100-9cff-7f31753425dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1547732901625618433:1fe5ca32-0be1-429c-b0d1-1021e36c7b88","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1548696909497466880:05972277-881e-4b96-9856-a0969db405b9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1548895423619817473:ddd75050-f7cd-477d-b9d8-0e4414d0898b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1551875362493194240:9bc25ec2-c167-447c-b443-924774f44dc6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1553649543459356672:8dd74d99-94eb-4aa4-b5ab-9eded346956d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1555461496154513409:79491bb9-f697-4612-82ee-a20ef0d58c27","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1557922706200432640:80c5e78e-2660-486a-b169-e8d6e5759f99","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1565252370904129536:43d6fe64-1947-45d4-934e-a7b9cd716f76","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1688671632687058944:22409e74-bbe8-478b-9ef7-9761f6aef8ec","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2038768237610144173:3d4ce52a-cbef-4e22-b6d8-12c8ad26ee8d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103363354056146986:16681616-06fe-4195-b9c8-dc0801eb6261","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103378003749425480:79a4bcf9-d873-492b-8e5b-e613ba0a0eef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103543988292555058:ea4e42b9-083c-4047-9c1a-d52a2fa69ecb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103849626893701447:bba6d78d-f188-4d88-961d-0a9ee91fddec","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104944877431853270:cca30e32-5db2-44d6-b08a-a4180e5004d5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113648256983138475:ccacb4ab-7953-48f4-9102-07f8de37e617","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113651052478091349:422cf0c1-e8ce-40fe-a1ba-459dd44a162e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113678818128904459:abf359c0-1148-4281-8056-37a5bc8a4a89","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:P9ZGKpkw-44","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:lZdDqS8P3UI","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":2,"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":35,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":41},"count":41,"evidence_window":{"end":"2026-10-23","start":"2018-11-01"},"retrieval_snapshot":"2026-10-31T10:45:44.771295Z","timeline":[{"count":1,"week":"2018-W44"},{"count":1,"week":"2020-W51"},{"count":5,"week":"2021-W24"},{"count":2,"week":"2021-W25"},{"count":6,"week":"2022-W26"},{"count":1,"week":"2022-W27"},{"count":3,"week":"2022-W28"},{"count":1,"week":"2022-W29"},{"count":2,"week":"2022-W30"},{"count":1,"week":"2022-W31"},{"count":1,"week":"2022-W32"},{"count":1,"week":"2022-W35"},{"count":3,"week":"2023-W32"},{"count":1,"week":"2024-W07"},{"count":1,"week":"2024-W13"},{"count":1,"week":"2026-W14"},{"count":5,"week":"2026-W39"},{"count":2,"week":"2026-W40"},{"count":3,"week":"2026-W43"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Tecentriq"],"label":"atezolizumab","slug":"atezolizumab"},{"brand_names":["Adriamycin","Rubex"],"label":"doxorubicin","slug":"doxorubicin"},{"brand_names":["Cytoxan","Frindovyx","Neosar"],"label":"cyclophosphamide","slug":"cyclophosphamide"},{"brand_names":["Taxol"],"label":"paclitaxel","slug":"paclitaxel"},{"brand_names":["Herceptin"],"label":"trastuzumab","slug":"trastuzumab"},{"brand_names":["Perjeta"],"label":"pertuzumab","slug":"pertuzumab"},{"brand_names":["Kadcyla"],"label":"trastuzumab emtansine","slug":"trastuzumab-emtansine"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Breast cancer","slug":"breast-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"IMpassion050","aliases":["IMpassion050","A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer","A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer"],"brief_title":"A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer","collaborators":["Chugai Pharmaceutical"],"conditions":["Breast Cancer"],"display_condition":"HER2-positive early breast cancer","display_interventions":[["atezolizumab"]],"enrollment":{"count":454,"type":"ACTUAL"},"interventions":[{"name":"Atezolizumab","synonyms":["Tecentriq"],"type":"DRUG"},{"name":"Placebo","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Doxorubicin","synonyms":["Adriamycin"],"type":"DRUG"},{"name":"Cyclophosphamide","synonyms":["Cytoxan","Neosar"],"type":"DRUG"},{"name":"Paclitaxel","synonyms":["Taxol"],"type":"DRUG"},{"name":"Trastuzumab","synonyms":["Herceptin"],"type":"DRUG"},{"name":"Pertuzumab","synonyms":["Perjeta"],"type":"DRUG"},{"name":"Trastuzumab Emtansine","synonyms":["Kadcyla"],"type":"DRUG"}],"nct_id":"NCT03726879","official_title":"A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer","overall_status":"COMPLETED","phase":["PHASE3"],"primary_completion_date":{"date":"2021-02-05","type":"ACTUAL"},"primary_endpoints":[{"description":"pCR is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy (NAST) (i.e., ypT0/is ypN0 in the current American Joint Committee on Cancer \\[AJCC\\] staging system, 8th edition). Treatment comparison was made using Cochran-Mantel-Haenszel test stratified by disease stage (T2 vs. T3-4) and hormone receptor status (estrogen receptor (ER) positive and/or progesterone receptor (PgR) positive vs. ER negative and PgR negative).","measure":"Percentage of Participants With Pathological Complete Response (pCR) in the PD-L1-Positive Population (IC 1/2/3)","timeFrame":"From randomization to approximately 6 months"},{"description":"pCR is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy (NAST) (i.e., ypT0/is ypN0 in the current American Joint Committee on Cancer \\[AJCC\\] staging system, 8th edition). Treatment comparison was made using Cochran-Mantel-Haenszel test stratified by disease stage (T2 vs. T3-4) and hormone receptor status (ER positive and/or PgR positive vs. ER negative and PgR negative).","measure":"pCR in the ITT Population","timeFrame":"From randomization to approximately 6 months"}],"registered_date":{"date":"2018-11-01","type":"ACTUAL"},"registry_last_updated":"2024-11-05","registry_url":"https://clinicaltrials.gov/study/NCT03726879","short_name":"IMpassion050","short_name_basis":"registry_acronym","sponsor":"Hoffmann-La Roche","start_date":{"date":"2019-01-11","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"BO40747","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}